Modality
Gene Editing
MOA
BiTE
Target
GIP-R
Pathway
Notch
CholangiocarcinomaALSAML
Development Pipeline
Preclinical
~Oct 2016
→ ~Jan 2018
Phase 1
Apr 2018
→ Feb 2030
Phase 1Current
NCT03930789
2,716 pts·Cholangiocarcinoma
2018-04→2030-02·Completed
2,716 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-02-133.9y awayInterim· Cholangiocarcinoma
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P1
Complet…
Catalysts
Interim
2030-02-13 · 3.9y away
Cholangiocarcinoma
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03930789 | Phase 1 | Cholangiocarcinoma | Completed | 2716 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| BII-8315 | Biogen | NDA/BLA | CDK2 |